Clinical Trials Browser

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT03158389 2023-09-28

N²M²

Phase 1/2 Completed

228 enrolled

CNS

Glioblastoma

NCT03809988 2023-09-07

PALMIRA

Phase 2 Completed

198 enrolled

Breast

Breast Neoplasms

NCT03065621 2023-04-19

NeoRHEA

Phase 2 Completed

100 enrolled

Breast

Breast Cancer Female

NCT03285568 2023-03-31

Patterns of Prescribing and Monitoring of Palbociclib

Completed

67 enrolled

Breast

Breast Neoplasms

NCT03110744 2023-03-27

NCT-PMO-1601

Phase 2 Completed

43 enrolled

Sarcoma

Chordoma

NCT03447132 2023-03-10

SAFIA

Phase 3 Completed

354 enrolled

Breast

Breast Neoplasms

NCT03969121 2023-03-10

Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer

Phase 3 Completed

141 enrolled

Breast

Breast Neoplasms

NCT04130152 2022-10-25

PROMETEO II

Phase EARLY_PHASE1 Completed

22 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual

NCT02448771 2022-10-24

A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer

Phase 1/2 Completed

36 enrolled 28 charts

Breast

Breast Neoplasms

NCT02806050 2022-10-12

Palbociclib and FES PET

Phase 2 Completed

30 enrolled

Breast

Breast Neoplasms

NCT02871791 2022-08-29

Palbociclib With Everolimus + Exemestane In BC

Phase 1/2 Completed

41 enrolled 12 charts

Breast

Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

NCT04874025 2022-08-08

PALBOSPAIN

Completed

815 enrolled

Breast

Breast Neoplasms

NCT03184090 2022-06-21

BioPER

Phase 2 Completed

33 enrolled

Breast

Breast Neoplasms

NCT04992156 2022-05-19

Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET

Completed

50 enrolled

Breast

Breast Neoplasms

NCT02384239 2022-03-16

A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer

Phase 2 Completed

70 enrolled 16 charts

Breast

Breast Neoplasms

NCT02400567 2022-03-15

NeoPAL

Phase 2 Completed

125 enrolled

Breast

Neoadjuvant Operable Breast Cancer

NCT01976169 2022-02-08

Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)

Phase 1 Completed

29 enrolled

Breast

Breast Neoplasms

Clinical Trials

Palbociclib and Cetuximab in Metastatic Colorectal Cancer

Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

PADA-1

CYCLIGIST

Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer

A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer

Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia

Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

ASPIRE

Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)

PARSIFAL

Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved

Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer

PADMA

PIPA

PEARL

Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

T-DM1

PATRICIA II

ETIC

Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer

PD 0332991 and Cetuximab in Patients With Incurable SCCHN

PENELOPE-B

Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer

Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors

N²M²

PALMIRA

NeoRHEA

Patterns of Prescribing and Monitoring of Palbociclib

NCT-PMO-1601

SAFIA

Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer

PROMETEO II

A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer

Palbociclib and FES PET

Palbociclib With Everolimus + Exemestane In BC

PALBOSPAIN

BioPER

Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET

A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer

NeoPAL

Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)